Metronidazole Tablet — Competitive Intelligence Brief

Metronidazole Tablet (Metronidazole Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antibiotic. Area: Infectious Disease.

marketed Nitroimidazole antibiotic Bacterial and parasitic DNA Infectious Disease Small molecule

Target snapshot

Metronidazole Tablet (Metronidazole Tablet) — Appili Therapeutics Inc.. Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole Tablet TARGET	Metronidazole Tablet	Appili Therapeutics Inc.	marketed	Nitroimidazole antibiotic	Bacterial and parasitic DNA
Metronidazole 250 (7 days)	Metronidazole 250 (7 days)	University of Guarulhos	marketed	Nitroimidazole antimicrobial	Bacterial and parasitic DNA
Metronidazole 400 (14 days)	Metronidazole 400 (14 days)	University of Guarulhos	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Azithromycin + Metronidazole	Azithromycin + Metronidazole	Sheikh Zayed Medical College	marketed	Macrolide antibiotic + Nitroimidazole antibiotic combination	Bacterial 50S ribosome (azithromycin); anaerobic bacterial DNA (metronidazole)
Metronidazole (ST14)	Metronidazole (ST14)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole (BQ10)	Metronidazole (BQ10)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole Suppositories	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antibiotic class)

1. National Taiwan University Hospital · 2 drugs in this class
2. Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · 2 drugs in this class
3. University of Guarulhos · 2 drugs in this class
4. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
5. LEO Pharma · 1 drug in this class
6. Sherief Abd-Elsalam · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. Appili Therapeutics Inc. · 1 drug in this class
10. bioRASI, LLC · 1 drug in this class